U.S. Precision Oncology Market Size & Outlook, 2025-2030
U.S. Precision Oncology Market, 2018-2030 (US$M)
Global Market
Related Markets
U.S. precision oncology market highlights
- The U.S. precision oncology market generated a revenue of USD 45,159.4 million in 2024 and is expected to reach USD 79,841.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of 10% from 2025 to 2030.
- In terms of segment, therapeutics was the largest revenue generating product in 2024.
- Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.
Precision oncology market data book summary
| Market revenue in 2024 | USD 45,159.4 million |
| Market revenue in 2030 | USD 79,841.2 million |
| Growth rate | 10% (CAGR from 2025 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Diagnostics |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | Thermo Fisher Scientific Inc, Invitae Corp, Qiagen NV, Illumina Inc, Exact Sciences Corp, Rain Oncology, Strata Oncology, Xilis, Variantyx, BioServe, Relay Therapeutics, Acrivon Therapeutics |
Other key industry trends
- In terms of revenue, U.S. accounted for 39.0% of the global precision oncology market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. precision oncology market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 79,841.2 million by 2030.
The precision oncology market in the U.S. is projected to grow at a significant CAGR during the forecast period. Significant approvals for innovative treatment regimens for various cancers are one of the prime factors driving the market. For instance, AstraZeneca’s Imfinzi (durvalumab) received FDA approval in August 2024 for use with chemotherapy in treating resectable early-stage non-small cell lung cancer.
Based on the AEGEAN Phase III trial, the Imfinzi-based regimen reduced the risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone. Such advancements demonstrate the growing adoption of precision therapies that enhance survival rates, driving the demand for personalized cancer treatments in the U.S., and thereby fostering market growth.
No credit card required*
Publish Date: Jan 22, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Precision Oncology Market Scope
Precision Oncology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Exact Sciences Corp | View profile | 6,600 | 5505 Endeavor Lane, Madison, WI, United States, 53719 | www.exactsciences.com |
| Invitae Corp | View profile | 1,700 | 1400 16th Street, San Francisco, CA, United States, 94103 | www.invitae.com |
| Rain Oncology | View profile | 101-250 | Newark, California, United States, North America | www.rainoncology.com |
| Strata Oncology | View profile | 51-100 | Ann Arbor, Michigan, United States, North America | www.strataoncology.com/ |
| Xilis | View profile | 51-100 | Durham, North Carolina, United States, North America | www.xilis.net |
| Variantyx | View profile | 101-250 | Framingham, Massachusetts, United States, North America | www.variantyx.com |
| BioServe | View profile | 51-100 | Beltsville, Maryland, United States, North America | bioserve.com |
U.S. Precision Oncology Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Precision Oncology Market Outlook will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 78.08% in 2024.
Horizon Databook has segmented the U.S. precision oncology market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The precision oncology market in the U.S. is projected to grow at a significant CAGR during the forecast period. Significant approvals for innovative treatment regimens for various cancers are one of the prime factors driving the market. For instance, AstraZeneca’s Imfinzi (durvalumab) received FDA approval in August 2024 for use with chemotherapy in treating resectable early-stage non-small cell lung cancer.
Based on the AEGEAN Phase III trial, the Imfinzi-based regimen reduced the risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone. Such advancements demonstrate the growing adoption of precision therapies that enhance survival rates, driving the demand for personalized cancer treatments in the U.S., and thereby fostering market growth.
- U.S. Precision Oncology Market Product Outlook (Revenue, USD Million , 2018-2030)
- Diagnostics
- Therapeutics
- U.S. Precision Oncology Market Cancer Outlook (Revenue, USD Million , 2018-2030)
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Prostate Cancer
- Lung Cancer
- Others
- U.S. Precision Oncology Market End Use Outlook (Revenue, USD Million , 2018-2030)
- Hospitals & Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Healthcare Data Companies
Reasons to subscribe to Precision Oncology Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Precision Oncology Market Outlook databook
- Our clientele includes a mix of Precision Oncology Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Precision Oncology Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Precision Oncology Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
U.S. Precision Oncology Market, 2018-2030 (US$M)
US Product - Precision Oncology Market Statistics, 2024 - 2030 (US$M)
